A Phase 1/2 interventional study of MEN2312 in Hematological Malignancy, sponsored by Stemline Therapeutics, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 424 are open to participants now.
This study's planned enrollment of 115 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →Stemline Therapeutics, Inc. is the lead sponsor of 23 studies on the registry; 7 are open to participants now.
First submitted after Stemline Therapeutics, Inc. became part of Menarini Group.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Renal Function:
Hepatic Function:
Cardiac Function:
Performance Status:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive escalating doses of MEN2312 orally once daily (QD) for all days of a 28-day treatment cycle.
Drug: MEN2312
Participants will receive MEN2312 (at a dose selected based on dose escalation Part A data) orally QD for all days of a 28-day treatment cycle.
Drug: MEN2312
Oral tablets
Part A: Number of Participants With Dose-limiting Toxicities (DLTs)
Time frame: Cycle 1 (28 days)
Part A: Number of Participants Experiencing Severe Toxicity
Time frame: Cycle 1 Day 1 through the completion of Cycle 4 (each cycle length = 28 days) (maximum duration: 112 days)
Part B: Overall Response Rate (ORR) per Central Laboratory Assessment
Time frame: Up to approximately 1.5 years
Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 1.5 years
Part A: Number of Participants With TEAEs
Time frame: Up to approximately 3.5 years
Part A: ORR Assessed Locally by the Investigator
Time frame: Up to approximately 3.5 years
Part A: Rate of Composite Complete Remission (CRc)
Time frame: Up to approximately 3.5 years
Part B: Rate of Complete Remission (CR)/Complete Remission With Partial Hematologic Recovery (CRh) per Central Laboratory Assessment
Time frame: Up to approximately 3.5 years
Part B: Rate of CRc per Central Laboratory Assessment
Time frame: Up to approximately 3.5 years
Part B: Time to First CR
Time frame: Up to approximately 3.5 years
Part B: Duration of CR
Time frame: Up to approximately 3.5 years
Part B: Time to First CR/CRh
Time frame: Up to approximately 3.5 years
Part B: Duration of CR/CRh
Time frame: Up to approximately 3.5 years
Part B: Time to First CRc
Time frame: Up to approximately 3.5 years
Part B: Duration of CRc
Time frame: Up to approximately 3.5 years
Part B: Time to First Overall Response
Time frame: Up to approximately 3.5 years
Part B: Duration of Overall Response
Time frame: Up to approximately 3.5 years
Part B: Rate of Measurable Residual Disease (MRD) Negativity as Assessed Locally
Time frame: Up to approximately 3.5 years
Part B: Event-free Survival (EFS)
Time frame: Up to approximately 3.5 years
Part B: Overall Survival (OS)
Time frame: Up to approximately 3.5 years
Part B: Percentage of Participants who Proceed to Hematopoietic Stem Cell Transplantation (HSCT)
Time frame: Up to approximately 3.5 years
Part A and Part B: Area Under the Curve (AUC) of MEN2312
Time frame: Cycle 1 Day 1 (during Part A only), Cycle 2 Day 8, and Cycle 1 Day 15 (each cycle length = 28 days)
Part A and Part B: Maximum Plasma Concentration (Cmax) of MEN2312
Time frame: Cycle 1 Day 1 (during Part A only), Cycle 2 Day 8, and Cycle 1 Day 15 (each cycle length = 28 days)
Part A and Part B: Time to Reach Cmax (Tmax) of MEN2312
Time frame: Cycle 1 Day 1 (during Part A only), Cycle 2 Day 8, and Cycle 1 Day 15 (each cycle length = 28 days)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for May 2028, 18 months later.
Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.